Genmab (CPSE:GMAB) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

GMAB Aperçu des actions

Genmab A/S développe des anticorps thérapeutiques pour le traitement du cancer et d'autres maladies, principalement au Danemark.

A propos de l'entreprise

GMAB analyse fondamentale
Score flocon de neige
Évaluation	5/6
Croissance future	4/6
Performances passées	5/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Se négocie à 76.4% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 21.07% par an

Les bénéfices ont augmenté de 19.4% au cours de l'année écoulée

Se négocie à un bon prix par rapport à ses pairs et au secteur

Analyse des risques

GMAB ont passé avec succès nos contrôles de risques.

Genmab A/S Concurrents

Bavarian Nordic

CPSE:BAVA

DKK 22.1b

H. Lundbeck

CPSE:HLUN B

DKK 42.2b

ALK-Abelló

CPSE:ALK B

DKK 35.7b

Neurocrine Biosciences

NasdaqGS:NBIX

US$15.0b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Genmab
Historique des cours de bourse
Prix actuel de l'action	DKK 1,844.00
Plus haut sur 52 semaines	DKK 2,710.00
Plus bas sur 52 semaines	DKK 1,691.00
Bêta	0.84
1Variation sur 1 mois	-2.02%
Variation sur 3 mois	-8.94%
Variation sur 1 an	-28.14%
3Variation sur 3 ans	-37.77%
Variation sur 5 ans	35.29%
Évolution depuis l'introduction en bourse	691.42%

Nouvelles et mises à jour récentes

Recent updates

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Apr 02

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Rendement pour les actionnaires

	GMAB	DK Biotechs	DK Marché
7D	1.4%	2.5%	-0.3%
1Y	-28.1%	3.9%	25.4%

Rendement vs Industrie: GMAB a sous-performé le secteur Danish Biotechs qui a rapporté 8.2 % au cours de l'année écoulée.

Rendement vs marché: GMAB a sous-performé le marché Danish qui a rapporté 27.3 % au cours de l'année écoulée.

Volatilité des prix

Is GMAB's price volatile compared to industry and market?
GMAB volatility
GMAB Average Weekly Movement	3.7%
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.3%
10% most volatile stocks in DK Market	9.1%
10% least volatile stocks in DK Market	2.8%

Cours de l'action stable: GMAB n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de GMAB ( 4% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1999	2,526	Jan G.J. de Winkel	www.genmab.com

Genmab A/S développe des anticorps thérapeutiques pour le traitement du cancer et d'autres maladies, principalement au Danemark. La société commercialise DARZALEX, un anticorps monoclonal humain pour le traitement des patients atteints de myélome multiple (MM), le teprotumumab pour le traitement des maladies oculaires de la thyroïde et l'amivantamab pour le traitement du cancer gastrique ou œsophagien avancé ou métastatique et du cancer du poumon non à petites cellules (NSCLC). Ses produits comprennent le daratumumab pour traiter le MM, les cancers du sang non-MM et l'amylose AL ; GEN1047 ; le tisotumab vedotin pour traiter les cancers du col de l'utérus, de l'ovaire et les cancers solides ; DuoBody-PD-L1x4-1BB, et DuoBody-CD40x4-1BB pour traiter les tumeurs solides ; Epcoritamab pour le traitement du lymphome diffus à grandes cellules B récidivant/réfractaire et de la leucémie lymphocytaire chronique ; et HexaBody-CD38 et GEN3017 pour le traitement des hémopathies malignes.

Genmab A/S Résumé des fondamentaux

Comment les bénéfices et les revenus de Genmab se comparent-ils à sa capitalisation boursière ?
GMAB statistiques fondamentales
Capitalisation boursière	DKK 115.59b
Bénéfices(TTM)	DKK 5.54b
Recettes(TTM)	DKK 19.02b

21.1x

Ratio P/E

6.2x

Ratio P/S

Le site GMAB est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
GMAB compte de résultat (TTM)
Recettes	DKK 19.02b
Coût des recettes	DKK 580.00m
Marge brute	DKK 18.44b
Autres dépenses	DKK 12.90b
Les revenus	DKK 5.54b

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

Nov 06, 2024

Résultat par action (EPS)	87.25
Marge brute	96.95%
Marge bénéficiaire nette	29.13%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de GMAB?

Voir les performances historiques et les comparaisons

GMAB Aperçu des actions

Récompenses

Analyse des risques

Genmab A/S Concurrents

CPSE:BAVA

DKK 22.1b

CPSE:HLUN B

DKK 42.2b

CPSE:ALK B

DKK 35.7b

NasdaqGS:NBIX

US$15.0b

Historique des prix et performances

Nouvelles et mises à jour récentes

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Recent updates

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching